One of the main considerations is ethical issues, such as privacy, consent, transparency, and accountability. Another consideration is effectiveness, as chatbots may not be able to provide the same quality of advice as human therapists. User experience is also important, as chatbots need to be optimized for ease of use and effectiveness. Finally, it is important to consider the limitations of chatbots and AI assistants, as they should be seen as a supplement, not a substitute, for human therapists.

Despite these considerations, the potential of AI therapy robots in elderly care is significant. They can help to manage chronic health conditions, reduce loneliness and social isolation, and provide emotional support. As research in this area continues to grow, it is likely that AI therapy robots will become an increasingly important tool in the care of older adults.

Paro

Paro is a therapeutic robot baby harp seal developed by Dr. Takanori Shibata of the National Institute of Advanced Industrial Science and Technology (AIST) in Japan. It was first released in 2004 and has since been used in hospitals, nursing homes, and other care facilities around the world.

Paro is covered in soft fur and has a realistic appearance and feel. It has five kinds of sensors: tactile, light, audition, temperature, and posture sensors, with which it can perceive people and its environment. Paro can respond to touch, sound, and light, and it can even learn to recognize individual people.

Paro is used to provide companionship and emotional support to people of all ages, but it is especially beneficial for those with dementia, autism, and other developmental disorders. Paro can help to reduce stress and anxiety, improve mood and motivation, and promote social interaction.

Studies have shown that Paro can have a number of positive benefits for people with dementia. For example, one study found that Paro helped to reduce agitation and aggression in dementia patients. Another study found that Paro helped to improve the quality of sleep in dementia patients.

Paro has also been shown to be beneficial for children with autism. For example, one study found that Paro helped to improve social interaction and communication skills in children with autism. Another study found that Paro helped to reduce anxiety and stress in children with autism.

Interacting with Paro has also shown to:

• Reduce pain.
• Improve cognitive function.
• Increase physical activity.
• Reduce loneliness and social isolation.
• Improve overall quality of life.

ElliQ

ElliQ is a voice-operated therapeutic robot designed to help older adults stay connected, informed, and engaged. It is a small, tabletop robot with a friendly personality and a wide range of capabilities. Some of the key features of ElliQ include:

• Conversational abilities: ElliQ can have conversations with users about a variety of topics, including current events, personal interests, and daily activities.
• Reminders and entertainment: ElliQ can provide reminders, play music, and games, and help users stay connected with loved ones.
• Adaptability: One of the most unique features of ElliQ is its ability to learn and adapt to the user’s individual needs and preferences. The more the user interacts with ElliQ, the better it gets to know them and the more tailored its responses become.

ElliQ has been shown to have a number of benefits for older adults, including reducing loneliness and social isolation, improving mood and well-being, increasing cognitive function, promoting physical activity, and helping to manage chronic health conditions. Here are some specific examples of how ElliQ can be used to help older adults:

• Medication and meal reminders: ElliQ can remind users to take their medication, eat their meals, and exercise.
• Staying connected with loved ones: ElliQ can help users stay connected with loved ones by sending them photos and videos, or by scheduling video calls.
• Staying informed: ElliQ can help users stay informed about current events and their local community by reading them news articles and upcoming events.
• Staying engaged: ElliQ can help users stay engaged by playing games, reading stories, and telling jokes.
• Emotional support: ElliQ can provide emotional support by listening to users’ concerns and offering words of encouragement.

ElliQ is still under development, but it has the potential to revolutionize the way we care for older adults. It is a valuable tool that can help to improve the quality of life for older adults and their caregivers.

Studies and Research involving ElliQ

• A recent study[1] found that of the three robots examined, ElliQ had the most sophisticated conversational ability and the most human-like presence despite lacking a human appearance.
• A clinical trial[2] evaluated the effect of ElliQ on reducing loneliness and social isolation in older adults. The study found that ElliQ was effective in reducing loneliness and social isolation in older adults.
• The first ElliQ impact studies[3] have shown that 80% of users report a reduction in loneliness, 82% experienced better mental health, and 90% feel more connected to the world around them.
• Another study[4] showed that an AI-driven companion robot like ElliQ can be an effective solution for alleviating loneliness in older adults.
• A report[5] on using ElliQ to stave off loneliness in older adults found that older adults aging in place on their own want something to converse and connect with when times get tough.
• The state of New York is distributing more than 800 ElliQ robots to the homes of the elderly[6]. The robots are designed to encourage independence among older adults living alone and provide companionship. NYSOFA director Greg Olsen says that ElliQ focuses on what matters to individuals: memories, life validation, interactions with friends and families, and promotes overall good health and well-being.

Overall, the studies and research suggest that ElliQ can be an effective tool for reducing loneliness and social isolation, improving mental health and well-being, and promoting overall health and well-being in older adults.

[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297987/
[2] https://classic.clinicaltrials.gov/ProvidedDocs/87/NCT03972787/Prot_SAP_000.pdf
[3] https://www.fiercehealthcare.com/health-tech/robot-bringing-companionship-seniors-elliq-gets-20-update-including-caregiver-app
[4] https://blog.elliq.com/2022-elliq-impact-report
[5] http://generations.asaging.org/staving-loneliness-social-robot
[6] https://www.theverge.com/2022/5/25/23140936/ny-state-distribute-home-robot-companions-nysofa-elliq

Mabu

Mabu is a virtual assistant designed to help people with chronic health conditions manage their treatment. It is a cloud-based platform that can be accessed from any device with an internet connection. Mabu is easy to use and does not require any technical expertise. It can be used to set reminders for medication, track symptoms, and communicate with healthcare providers. Mabu can also be used to access educational resources and support groups.

Mabu is a valuable tool for people with chronic health conditions because it can help them to stay organized and on top of their treatment. It can also help them to feel more connected to their healthcare team and to other people with similar conditions. Here are some specific examples of how Mabu can be used to help people with chronic health conditions:

• Mabu can remind users to take their medication on time and in the correct dosage.
• Mabu can track symptoms and provide insights into how the user’s condition is progressing.
• Mabu can help users to communicate with their healthcare providers by sending them messages and tracking their progress.
• Mabu can provide users with access to educational resources about their condition and its management.
• Mabu can help users to connect with support groups and other people with similar conditions.

Mabu is currently in a pilot phase and is being used by a limited number of users. However, the company plans to make Mabu more widely available in the near future. Studies and research have shown that virtual assistants like Mabu can be effective in improving medication adherence and reducing medical appointments. The evidence base for the use of interactive virtual health assistants is rapidly growing in both size and quality.

There are numerous other AI assistants that similar to Mabu. Mabu only serves an example of recent developments.

Considerations and Challenges

When it comes to AI therapy bots and assistants, there are several main considerations to keep in mind. These include ethical issues, effectiveness, user experience, and limitations.

Ethical issues arise when using chatbots in mental health, such as privacy, consent, transparency, and accountability. It is important to ensure transparency in chatbot interactions, obtain proper consent for data collection and use, and ensure that the chatbot is not biased against certain groups of people.

Effectiveness is another consideration. While chatbots can be effective in providing therapy, they are still limited in the quality of advice they can give. They may not pick up on information that a human would notice as indicative of a problem, and they may struggle to provide effective solutions to complex situations.

User experience is also important. Optimizing chatbots and AI assistants involves user experience and usability testing. User experience (UX) looks at the customer’s perception of the chatbot’s ease of use, efficiency, and effectiveness.

Finally, it is important to consider the limitations of chatbots. They are still limited in their ability to provide therapy and should not be seen as a substitute for human therapists. They may not be appropriate for clinical settings where trust and accuracy are paramount.

Conclusion

Overall, while AI therapy bots and assistants have the potential to be a valuable tool in mental health care, it is important to consider their limitations and ethical implications. They should be seen as a supplement, not a substitute, for human therapists.

The study, conducted by researchers at Mass General Brigham, New York’s Albert Einstein College of Medicine and Boston Children’s Hospital, looked at the responses of four voice assistants — Amazon’s Alexa, Apple’s Siri, Google Assistant’s Nest Mini, and Microsoft’s Cortana — to eight verbal questions about CPR. The questions were asked by actors pretending to be bystanders who had found an unconscious person.

Findings

The study found that the voice assistants provided inconsistent and inaccurate information about CPR. For example, one voice assistant suggested calling 911, while another suggested searching the internet for information. Only one voice assistant provided clear and accurate instructions on how to perform CPR.

The study found that AI guidance was less effective than human guidance in terms of providing relevant, consistent and timely information and instructions.

The challenges of AI-guided CPR

There are a number of challenges to developing AI systems that can effectively guide CPR. One challenge is that CPR is a complex procedure with many steps. Another challenge is that the effectiveness of CPR can vary depending on the circumstances, such as the age and health of the victim.

AI systems also need to be able to understand the context of a situation and adapt their instructions accordingly. For example, an AI system might need to provide different instructions for CPR on a child than on an adult.

The future of AI-guided CPR

Despite the challenges, there is potential for AI to play a role in guiding CPR. AI systems could be used to provide real-time feedback to bystanders who are performing CPR. They could also be used to train people in CPR.

However, more research and development is needed before AI can be used to replace human guidance in CPR. In the meantime, it is important for people to learn CPR from a qualified instructor.

Halicin

One example of an AI-discovered drug is Halicin, a powerful antibiotic that can kill many species of antibiotic-resistant bacteria. Halicin was discovered using artificial intelligence by researchers at MIT. The drug works in a different way to existing antibacterials and is the first of its kind to be found by setting AI loose on vast digital libraries of pharmaceutical compounds.

Benefits of AI-Driven Drug Discovery

One of the most promising applications of AI in drug discovery is in the identification of new drug targets. AI can be used to analyze large amounts of biological data to identify potential drug targets that are associated with specific diseases. This can help researchers focus their efforts on the most promising targets, and avoid wasting time and resources on targets that are unlikely to be successful.

AI can also be used to design new molecules that have the desired properties for a particular drug. This can be done by using AI to search through vast databases of chemical compounds and identify those that are most likely to be effective and safe. AI can also be used to optimize the structure of existing molecules to improve their efficacy or reduce their side effects.

In addition to identifying new drug targets and designing new molecules, AI can also be used to predict the efficacy and safety of potential drugs. This can help researchers avoid wasting time and money on drugs that are unlikely to be successful. AI can also be used to optimize the clinical trial process, which can help to speed up the development of new drugs.

Challenges and Limitations of AI-Assisted Drug Discovery

• One challenge is the quality of the data used to train the AI model. If the data is not accurate or representative, the model will not be able to make accurate predictions.
• Another challenge is the regulatory environment. There are currently no clear guidelines or standards for validating and approving AI-based drugs. This can make it difficult for pharmaceutical companies to bring AI-discovered drugs to market.

Some Examples of AI-Driven Drug Discovery Companies

• BenevolentAI: A UK-based company that uses its own platform to discover new medicines for various diseases such as Parkinson’s disease, Alzheimer’s disease, ALS, ulcerative colitis, etc.
• Atomwise: A US-based company that uses its AtomNet platform to design new molecules using deep learning and generative models. It has partnered with several pharma companies and academic institutions to discover new drugs for cancer, infectious diseases, neurological disorders, etc.
• Insilico Medicine: A US-based company that uses its generative chemistry platform to design novel molecules with desired properties. It also uses its target discovery platform to identify new targets for aging-related diseases such as sarcopenia, fibrosis, etc.
• Cyclica: A Canada-based company that uses its Ligand Express platform to screen large libraries of compounds against multiple targets using deep learning. It also offers services such as polypharmacology profiling, adverse event prediction, drug repurposing, etc.
• BERG: A US-based company that uses its Interrogative Biology platform to analyze biological data using AI and machine learning. It aims to discover new drugs for cancer, diabetes, obesity, etc.
• NuMedii: A US-based company that uses its Artificial Intelligence for Drug Discovery (AIDD) platform to discover new drugs for complex diseases such as idiopathic pulmonary fibrosis (IPF), systemic sclerosis (SSc), etc. It uses big data analytics and machine learning to identify novel targets and drug candidates.

The use of AI in drug discovery is still in its early stages, but it has the potential to revolutionize the field. As AI algorithms continue to improve and more high-quality data becomes available, AI is likely to play an increasingly important role in the discovery of new drugs.

A systematic review and meta-analysis of 19 trials has found that chatbot interventions are efficacious for improving physical activity, diet quality, sleep duration, and quality. The trials included a total of 2,547 participants aged 9 to 71 years. Most interventions (79%) targeted physical activity, and most trials were of low quality.

Outcomes of interest

Outcomes of interest were

1. total physical activity (any measure of low, moderate and/or vigorous intensity physical activity reported as a duration, e.g., minutes per day or week),
2. moderate-to-vigorous physical activity only (MVPA, minutes/week), (
3. daily steps,
4. fruit and vegetable consumption,
5. sleep quality and
6. sleep duration.

Findings

The review found that chatbot interventions significantly increased total physical activity, steps, moderate-to-vigorous physical activity (MVPA), fruit and vegetable consumption, sleep duration, and sleep quality. Text-based and artificial intelligence (AI) chatbots were more effective than voice chatbots for diet. Multicomponent interventions (i.e., those that included other interventions in addition to the chatbot) were more effective than chatbot-only interventions for sleep.

The review concluded that chatbot interventions are efficacious for improving physical activity, diet quality, sleep duration, and quality across populations, age groups, durations, and as standalone or part of multicomponent interventions. The review also found that chatbot interventions were more effective than other interventions, such as text messaging and telephone calls.

The findings of this review suggest that chatbots can be a promising tool for improving health behaviors. Chatbots are convenient, accessible, and can be tailored to individual needs. They can also provide personalized feedback and support. Future research should focus on developing high-quality chatbot interventions and evaluating their long-term effectiveness.

Additional Points

• The review found that chatbot interventions were more effective for people who were less motivated to change their health behaviors.
• Chatbots can be used to provide information, reminders, and encouragement.
• Chatbots can also be used to track progress and provide feedback.
• Chatbots can be used to connect people with other resources, such as fitness classes or community support groups.

Source: Systematic review and meta-analysis of the effectiveness of chatbots on lifestyle behaviours